Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results

LESSONS LEARNED. Despite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing. Safety was documented, although dose escalation was...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: O'Reilly, Eileen M., Roach, James, Miller, Paul, Yu, Kenneth H., Tjan, Catherine, Rosano, Molly, Krause, Silva, Avery, William, Wolf, Julie, Flaherty, Keith, Nix, Darrell, Ryan, David P.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728039/
https://ncbi.nlm.nih.gov/pubmed/29158367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0472
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados